Nicotinic acetylcholine receptors in the pathophysiology of al zheimer’s disease: The role of protein-protein interactions in current and future treatment

Current Pharmaceutical Design

Volumn 22, Issue 14, 2016, Pages 2015-2034

  Thomsen, Morten Skøtt ^a   Andreasen, Jesper Tobias ^a   Arvaniti, Maria ^a   Kohlmeier, Kristi Anne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amyloid; Cognition; Ly 6 uPAR; Lynx; Nicotine; NMDA; Wnt; catenin

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 4 [(5 PHENYL 1,3,4 THIADIAZOL 2 YL)OXY] 1 AZONIATRICYCLO[3.3.1.1 3,7]DECANE 3,4 DICARBOXY 3 HYDROXYBUTANOATE; AMYLOID BETA PROTEIN; AZD 1446; BETA CATENIN; CHOLINERGIC RECEPTOR STIMULATING AGENT; ENCENICLINE; ISPRONICLINE; LYNX PROTEIN; MEM 3454; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; POZANICLINE; UNCLASSIFIED DRUG; VARENICLINE; WNT PROTEIN; NICOTINIC AGENT; PROTEIN BINDING;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; CHOLINERGIC SYSTEM; COGNITION; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SMOKING; WNT SIGNALING PATHWAY; ANIMAL; COGNITIVE DEFECT; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; ANIMALS; COGNITIVE DYSFUNCTION; HUMANS; NICOTINIC AGONISTS; PROTEIN BINDING; RECEPTORS, NICOTINIC;

EID: 84969172352     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160127112357     Document Type: Article

References (308)

1. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
3. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-6.
4. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
5. Deiana S, Platt B, Riedel G. The cholinergic system and spatial learning. Behav Brain Res 2011; 221: 389-411.
6. Moruzzi G, Magoun HW. Brain stem reticular formation and activation of the EEG. Electroencephalogr Clin Neurophysiol 1949; 1: 455-73.
7. Pinto T, Lanctot KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev 2011; 10: 404-12.
8. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73-120.
9. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006; 27: 482-91.
10. Gotti C, Moretti M, Bohr I, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 2006; 23: 481-9.
11. Pym L, Kemp M, Raymond-Delpech V, Buckingham S, Boyd CA, Sattelle D. Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes. Br J Pharmacol 2005; 146: 964-71.
12. Good CH, Bay KD, Buchanan R, Skinner RD, Garcia-Rill E. Muscarinic and nicotinic responses in the developing pedunculopontine nucleus (PPN). Brain Res 2007; 1129: 147-55.
13. Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG. Fine a. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001; 21: 7993-8003.
14. Rousseau SJ, Jones IW, Pullar IA, Wonnacott S. Presynaptic alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate [3H] d-aspartate release from rat frontal cortex in vitro. Neuropharmacology 2005; 49: 59-72.
15. Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. alpha7 nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 2000; 393: 59-67.
16. Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J Neurosci 1999; 19: 2693-705.
17. McQuiston aR, Madison DV. Nicotinic receptor activation excites distinct subtypes of interneurons in the rat hippocampus. J Neurosci 1999; 19: 2887-96.
18. Alkondon M, Pereira EF, Barbosa CT, Albuquerque EX. Neuronal nicotinic acetylcholine receptor activation modulates gammaaminobutyric acid release from CA1 neurons of rat hippocampal slices. J Pharmacol Exp Ther 1997; 283: 1396-411.
19. Bennett C, Arroyo S, Berns D, Hestrin S. Mechanisms Generating Dual-Component Nicotinic EPSCs in Cortical Interneurons. J Neurosci 2012; 32: 17287-96.
20. Sarter M, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci 2009; 10: 383-90.
21. Fucile S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium 2004; 35: 1-8.
22. McKay BE, Placzek AN, Dani JA. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007; 74: 1120-33.
23. Miwa JM, Freedman R, Lester HA. Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 2011; 70: 20-33.
24. Dominguez del Toro E, Juiz JM, Peng X, Lindstrom J, Criado M. Immunocytochemical localization of the alpha 7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system. J Comparative Neurol 1994; 349: 325-342.
25. Jones S, Yakel JL. Functional nicotinic ACh receptors on interneurones in the rat hippocampus. J Physiol 1997; 504: 603-10.
26. Frazier CJ, Buhler AV, Weiner JL, Dunwiddie TV. Synaptic potentials mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J Neurosci 1998; 18: 8228-35.
27. Moretti M, Zoli M, George AA, et al. The Novel 72-nicotinic acetylcholine receptor subtype is expressed in mouse and human basal forebrain: biochemical and pharmacological characterisation. Mol Pharmacol 2014; 86: 306-17.
28. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009; 29: 918-29.
29. Thomsen MS, Zwart R, Ursu D, et al. Mikkelsen. 7 and 2 nicotinic acetylcholine receptor subunits form heteromeric receptor complexes that are expressed in the human cortex and display distinct pharmacological properties. PLoS One 2015; 10: e0130572.
30. Liu Z, Tearle AW, Nai Q, Berg DK. Rapid activity-driven SNAREdependent trafficking of nicotinic receptors on somatic spines. J Neurosci 2005; 25: 1159-68.
31. Frotscher M, Vida I, Bender R. Evidence for the existence of non-GABAergic, cholinergic interneurons in the rodent hippocampus. Neuroscience 2000; 96: 27-31.
32. Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 2001; 86: 3043-55.
33. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996; 383: 713-6.
34. Welsby P, Rowan M, Anwyl R. Nicotinic receptor-mediated enhancement of long-term potentiation involves activation of metabotropic glutamate receptors and ryanodine-sensitive calcium stores in the dentate gyrus. Eur J Neurosci 2006; 24: 3109-18.
35. Ondrejcak T, Wang Q, Kew JN, et al. Activation of alpha7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents Ass-mediated inhibition of LTP in the rat hippocampus. Eur J Pharmacol 2012; 677: 63-70.
36. Kroker KS, Rast G, Rosenbrock H. Differential effects of subtypespecific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP. Eur J Pharmacol 2011; 671: 26-32.
37. Ji D, Lape R, Dani JA. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 2001; 31: 131-41.
38. Golland Y, Bentin S, Gelbard H, et al. Extrinsic and intrinsic systems in the posterior cortex of the human brain revealed during natural sensory stimulation. Cereb Cortex 2007; 17: 766-77.
39. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The national institute on aging, and reagan institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's Disease. Neurobiol Aging 1997; 18: S1-2.
40. Woolf NJ, Butcher LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011; 221: 488-98.
41. Passetti F, Dalley JW, O'Connell MT, Everitt BJ, Robbins TW. Increased acetylcholine release in the rat medial prefrontal cortex during performance of a visual attentional task. Eur J Neurosci 2000; 12: 3051-8.
42. Gill TM, Sarter M, Givens B. Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J Neurosci 2000; 20: 4745-57.
43. Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 1993; 90: 5194-8.
44. van der Zee EA, Streefland C, Strosberg AD, Schroder H, Luiten PG. Visualization of cholinoceptive neurons in the rat neocortex: colocalization of muscarinic and nicotinic acetylcholine receptors. Brain Res Mol Brain Res 1992; 14: 326-36.
45. Clarke PB, Pert CB, Pert A. Autoradiographic distribution of nicotine receptors in rat brain. Brain Res 1984; 323: 390-5.
46. Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat brain: autoradiographic comparison of [3H] acetylcholine, [3H] nicotine, and [125I] -alpha-bungarotoxin. J Neurosci 1985; 5: 1307-15.
47. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-122.
48. O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 2002; 1: 399-411.
49. Thomsen MS, Hansen HH, Timmermann DB, Mikkelsen JD. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010; 16: 323-43.
50. Gioanni Y, Rougeot C, Clarke PB, Lepouse C, Thierry AM, Vidal C. Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur J Neurosci 1999; 11: 18-30.
51. Disney AA, Aoki C, Hawken MJ. Gain modulation by nicotine in macaque v1. Neuron 2007; 56: 701-13.
52. Duffy AM, Zhou P, Milner TA, Pickel VM. Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse. 2009; 161(4): 1091-103.
53. Levy RB, Aoki C. Alpha7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex. J Neurosci 2002; 22: 5001-15.
54. Lubin M, Erisir A, Aoki C. Ultrastructural immunolocalization of the alpha 7 nAChR subunit in guinea pig medial prefrontal cortex. Annl N Y Acad Sci 1999; 868: 628-32.
55. Nakayama H, Shioda S, Okuda H, Nakashima T, Nakai Y. Immunocytochemical localization of nicotinic acetylcholine receptor in rat cerebral cortex. Brain Res Mol Brain Res 1995; 32: 321-8.
56. Wevers A, Jeske A, Lobron C, et al. Cellular distribution of nicotinic acetylcholine receptor subunit mRNAs in the human cerebral cortex as revealed by non-isotopic in situ hybridization. Brain Res Mol Brain Res 1994; 25: 122-8.
57. Chu ZG, Zhou FM, Hablitz JJ. Nicotinic acetylcholine receptormediated synaptic potentials in rat neocortex. Brain Res 2000; 887: 399-405.
58. Roerig B, Nelson DA, Katz LC. Fast synaptic signaling by nicotinic acetylcholine and serotonin 5-HT3 receptors in developing visual cortex. J Neurosci 1997; 17: 8353-62.
59. Zolles G, Wagner E, Lampert A, Sutor B. Functional expression of nicotinic acetylcholine receptors in rat neocortical layer 5 pyramidal cells. Cereb Cortex 2009; 19: 1079-91.
60. Kassam SM, Herman PM, Goodfellow NM, Alves NC, Lambe EK. Developmental excitation of corticothalamic neurons by nicotinic acetylcholine receptors. J Neurosci 2008; 28: 8756-64.
61. Yang Y, Paspalas CD, Jin LE, Picciotto MR, Arnsten AFT, Wang M. Nicotinic 7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc Natl Acad Sci USA 2013; 110: 12078-83.
62. Poorthuis RB, Bloem B, Schak B, Wester J, de Kock CP, Mansvelder HD. Layer-specific modulation of the prefrontal cortex by nicotinic acetylcholine receptors. Cereb Cortex 2013; 23: 148-61.
63. Hedrick T, Waters J. Acetylcholine excites neocortical pyramidal neurons via nicotinic receptors. J Neurophysiol 2015; 113(7): 2195-209.
64. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011; 36: 52-73.
65. Sarter M, Hasselmo ME, Bruno JP, Givens B. Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain research. Brain Res Rev 2005; 48: 98-111.
66. Moretti DV. Theta and alpha EEG frequency interplay in subjects with mild cognitive impairment: evidence from EEG, MRI, and SPECT brain modifications. Front Aging Neurosci 2015; 7: 31.
67. Gallego-Jutgla E, Sole-Casals J, Vialatte FB, Dauwels J, Cichocki A. A theta-band EEG based index for early diagnosis of Alzheimer's disease. J Alzheimers Dis 2015; 43: 1175-84.
68. Kramis R, Vanderwolf CH, Bland BH. Two types of hippocampal rhythmical slow activity in both the rabbit and the rat: relations to behavior and effects of atropine, diethyl ether, urethane, and pentobarbital. Exp Neurol 1975; 49: 58-85.
69. Jeewajee A, Lever C, Burton S, O'Keefe J, Burgess N. Environmental novelty is signaled by reduction of the hippocampal theta frequency. Hippocampus 2008; 18: 340-8.
70. Buzsaki G. Theta oscillations in the hippocampus. Neuron 2002; 33: 325-40.
71. Cape EG, Manns ID, Alonso A, Beaudet A, Jones BE. Neurotensin-induced bursting of cholinergic basal forebrain neurons promotes gamma and theta cortical activity together with waking and paradoxical sleep. J Neurosci 2000; 20: 8452-61.
72. Manns ID, Alonso A, Jones BE. Discharge properties of juxtacellularly labeled and immunohistochemically identified cholinergic basal forebrain neurons recorded in association with the electroencephalogram in anesthetized rats. J Neurosci 2000; 20: 1505-18.
73. Petsche H, Stumpf C, Gogolak G. The significance of the rabbit's septum as a relay station between the midbrain and the hippocampus. I. The control of hippocampus arousal activity by the septum cells. Electroencephalogr Clin Neurophysiol 1962; 14: 202-11.
74. Bland BH. The physiology and pharmacology of hippocampal formation theta rhythms. Prog Neurobiol 1986; 26: 1-54.
75. Lu CB, Li CZ, Li DL, Henderson Z. Nicotine induction of theta frequency oscillations in rodent medial septal diagonal band in vitro. Acta Pharmacol Sin 2013; 34: 819-29.
76. Henderson Z, Boros A, Janzso G, Westwood AJ, Monyer H, Halasy K. Somato-dendritic nicotinic receptor responses recorded in vitro from the medial septal diagonal band complex of the rodent. J Physiol 2005; 562: 165-82.
77. Siok CJ, Rogers JA, Kocsis B, Hajos M. Activation of alpha7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation. Eur J Neurosci 2006; 23: 570-4.
78. Stoiljkovic M, Kelley C, Nagy D, Hajos M. Modulation of hippocampal neuronal network oscillations by alpha7 nACh receptors. Biochem Pharmacol 2015; 97(4): 445-53.
79. Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci 2009; 32: 209-24.
80. Steriade M, Amzica F. Intracortical and corticothalamic coherency of fast spontaneous oscillations. Proc Natl Acad Sci USA 1996; 93: 2533-8.
81. Singer W. Synchronization of cortical activity and its putative role in information processing and learning. Annu Rev Physiol 1993; 55: 349-74.
82. Womelsdorf T, Schoffelen JM, Oostenveld R, et al. Modulation of neuronal interactions through neuronal synchronization. Science 2007; 316: 1609-12.
83. Huang C, Wahlund L, Dierks T, Julin P, Winblad B, Jelic V. Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin Neurophysiol 2000; 111: 1961-7.
84. Jelic V, Shigeta M, Julin P, Almkvist O, Winblad B, Wahlund LO. Quantitative electroencephalography power and coherence in Alzheimer's disease and mild cognitive impairment. Dementia 1996; 7: 314-23.
85. van Deursen JA, Vuurman EF, Verhey FR, van Kranen-Mastenbroek VH, Riedel WJ. Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. J Neural Transm 2008; 115: 1301-11.
86. Jeong J. EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol 2004; 115: 1490-505.
87. Wang Y, Wang Z, Wang J, et al. The modulation of nicotinic acetylcholine receptors on the neuronal network oscillations in rat hippocampal CA3 area. Sci Rep 2015; 5: 9493.
88. Aracri P, Consonni S, Morini R, Perrella M, Rodighiero S, Amadeo A, Becchetti A. Tonic modulation of GABA release by nicotinic acetylcholine receptors in layer v of the murine prefrontal cortex. Cerebral Cortex 2010; 20: 1539-55.
89. Song C, Murray TA, Kimura R, et al. Role of alpha7-nicotinic acetylcholine receptors in tetanic stimulation-induced gamma oscillations in rat hippocampal slices. Neuropharmacology 2005; 48: 869-80.
90. Featherstone RE, Phillips JM, Thieu T, et al. Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials. PLoS One 2012; 7: e39775.
91. Whittington MA, Traub RD, Jefferys JG. Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. Nature 1995; 373: 612-5.
92. Wang XJ, Buzsaki G. Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model. J Neurosci 1996; 16: 6402-13.
93. Tiesinga P, Sejnowski TJ. Cortical enlightenment: are attentional gamma oscillations driven by ING or PING? Neuron 2009; 63: 727-32.
94. Rodriguez R, Kallenbach U, Singer W, Munk MH. Short-and long-term effects of cholinergic modulation on gamma oscillations and response synchronization in the visual cortex. J Neurosci 2004; 24: 10369-78.
95. Steriade M, Contreras D, Amzica F, Timofeev I. Synchronization of fast (30-40 Hz) spontaneous oscillations in intrathalamic and thalamocortical networks. J Neurosci 1996; 16: 2788-808.
96. Steriade M, Amzica F, Contreras D. Synchronization of fast (30-40 Hz) spontaneous cortical rhythms during brain activation. J Neurosci 1996; 16: 392-417.
97. Buzsaki G, Gage FH. The cholinergic nucleus basalis: a key structure in neocortical arousal. EXS 1989; 57: 159-71.
98. Duque A, Balatoni B, Detari L, Zaborszky L. EEG correlation of the discharge properties of identified neurons in the basal forebrain. J Neurophysiol 2000; 84: 1627-35.
99. Bryant AS, Goddard CA, Huguenard JR, Knudsen EI. Cholinergic control of gamma power in the midbrain spatial attention network. J Neurosci 2015; 35: 761-75.
100. Disney AA, Aoki C. Muscarinic acetylcholine receptors in macaque V1 are most frequently expressed by parvalbuminimmunoreactive neurons. J Comp Neurol 2008; 507: 1748-62.
101. Disney AA, Domakonda KV, Aoki C. Differential expression of muscarinic acetylcholine receptors across excitatory and inhibitory cells in visual cortical areas V1 and V2 of the macaque monkey. J Comp Neurol 2006; 499: 49-63.
102. Parikh V, Sarter M. Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity. Ann N Y Acad Sci 2008; 1129: 225-35.
103. Slotkin TA, Seidler FJ, Crain BJ, Bell JM, Bissette G, Nemeroff CB. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proc Natl Acad Sci USA 1990; 87: 2452-5.
104. Lai MK, Tsang SW, Garcia-Alloza M, et al. Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. Neurobiol Dis 2006; 22: 555-61.
105. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-44.
106. Buckingham SD, Jones AK, Brown LA, Sattelle DB. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 2009; 61: 39-61.
107. Jurgensen S, Ferreira ST. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci 2010; 40: 221-9.
108. Lombardo S, Maskos U. Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment. Neuropharmacology 2015; 96(Pt B): 255-62.
109. Carson R, Craig D, Hart D, et al. Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromol Med 2008; 10: 377-84.
110. Carson R, Craig D, McGuinness B, et al. Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. J Med Genet 2008; 45(4): 244-8.
111. Kawamata J, Shimohama S. Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. J Alzheimers Dis 2002; 4: 71-6.
112. Cook LJ, Ho LW, Taylor AE, et al. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci Lett 2004; 358: 142-6.
113. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38(1): 22-33.
114. Kendziorra K, Wolf H, Meyer PM, et al. Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2011; 38: 515-25.
115. D'Andrea MR, Nagele RG. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr Pharm Des 2006; 12: 677-84.
116. Banerjee C, Nyengaard JR, Wevers A, et al. Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease--a stereological approach. Neurobiol Dis 2000; 7: 666-72.
117. Burghaus L, Schütz U, Krempel U, et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain research. Mol Brain Res 2000; 76: 385-8.
118. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43.
119. Wevers A. Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav Brain Res 2000; 113: 207-15.
120. Martin-Ruiz CM, Court JA, Molnar E, et al. Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. J Neurochem 1999; 73: 1635-40.
121. Warpman U, Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 1995; 6: 2419-23.
122. Okada H, Ouchi Y, Ogawa M, et al. Alterations in 42 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Brain A J Neurol 2013; 136: 3004-17.
123. Perry E, Martin-Ruiz C, Lee M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000; 393: 215-22.
124. Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006; 188: 509-20.
125. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005; 192: 215-25.
126. Wevers A, Monteggia L, Nowacki S, et al. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 1999; 11: 2551-65.
127. Koval L, Lykhmus O, Kalashnyk O, et al. The presence and origin of autoantibodies against alpha4 and alpha7 nicotinic acetylcholine receptors in the human blood: possible relevance to Alzheimer's pathology. J Alzheimers Dis 2011; 25: 747-61.
128. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 2014; 5: 88.
129. Apelt J, Kumar A, Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res 2002; 953: 17-30.
130. Bednar I, Paterson D, Marutle A, et al. Selective nicotinic receptor consequences in APP(SWE) transgenic mice. Mol Cell Neurosci 2002; 20: 354-65.
131. Jones IW, Westmacott A, Chan E, et al. Alpha7 nicotinic acetylcholine receptor expression in Alzheimer's disease: receptor densities in brain regions of the APP(SWE) mouse model and in human peripheral blood lymphocytes. J Mol Neurosci 2006; 30: 83-4.
132. Xiao Y, Shan KR, Guan ZZ. Effect of beta-amyloid peptides on alpha-7 nicotinic receptor status in astrocytes and neurons, and its relationship to pathogenesis of Alzheimer's disease. Zhonghua Bing Li Xue Za Zhi 2006; 35: 462-6.
133. Marutle A, Unger C, Hellstrom-Lindahl E, et al. Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. Neurosci Lett 2002; 328: 269-72.
134. Mousavi M, Nordberg A. Expression of the alpha7, alpha4 and alpha3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and beta-amyloid. Int J Dev Neurosci 2006; 24: 269-73.
135. Teaktong T, Graham AJ, Court JA, et al. Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. J Neurol Sci 2004; 225: 39-49.
136. Teaktong T, Graham A, Court J, et al. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 2003; 41: 207-11.
137. Matsumura A, Suzuki S, Iwahara N, et al. Temporal changes of CD68 and 7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. J Alzheimer's Dis JAD 2014.
138. Liu Q, Xie X, Emadi S, Sierks MR, Wu J. A novel nicotinic mechanism underlies beta-amyloid-induced neurotoxicity. Neuropharmacology 2015; 97: 457-63.
139. Viel TA, Caetano AL, Albuquerque MS, Araujo MS, Buck HS. Chronic infusion of amyloid-beta peptide and sustained attention altered alpha7 nicotinic receptor density in the rat brain. Curr Alzheimer Res 2012; 9: 1210-20.
140. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 2009; 29: 8805-15.
141. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 2010; 30: 2442-53.
142. Lykhmus O, Voytenko L, Koval L, et al. 7 Nicotinic Acetylcholine Receptor-Specific Antibody Induces Inflammation and Amyloid 42 Accumulation in the Mouse Brain to Impair Memory. PloS One 2015; 10: e0122706.
143. Puzzo D, Privitera L, Fa M, et al. Endogenous amyloid-is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011; 69: 819-30.
144. Piras S, Furfaro AL, Piccini A, et al. Monomeric A1–42 and RAGE: key players in neuronal differentiation. Neurobiol Aging 2014; 35: 1301-8.
145. Dawkins E, Small DH. Insights into the physiological function of the -amyloid precursor protein: Beyond Alzheimer's disease. J Neurochem 2014; 129: 756-69.
146. Seabrook GR, Smith DW, Bowery BJ, et al. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 1999; 38: 349-59.
147. Querfurth HW, LaFerla FM. Alzheimer's disease. New Engl J Med 2010; 362: 329-44.
148. Virok DP, Simon D, Bozso Z, et al. Protein array based interactome analysis of amyloid-beta indicates an inhibition of protein translation. J Proteome Res 2011; 10: 1538-47.
149. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-32.
150. Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 2000; 75: 1155-61.
151. Soderman A, Thomsen MS, Hansen HH, et al. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain Res 2008; 1227: 240-7.
152. Maatuk N, Samson AO. Modeling the binding mechanism of Alzheimer's A1-42 to nicotinic acetylcholine receptors based on similarity with snake neurotoxins. Neurotoxicology 2013; 34: 236-42.
153. Small DH, Maksel D, Kerr ML, et al. The beta-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the alpha7 nicotinic acetylcholine receptor. J Neurochem 2007; 101: 1527-38.
154. Pettit DL, Shao Z, Yakel JL. beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 2001; 21: RC120.
155. Dougherty JJ, Wu J, Nichols RA. Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 2003; 23: 6740-7.
156. Wu J, Kuo YP, George AA, Xu L, Hu J, Lukas RJ. beta-Amyloid directly inhibits human alpha4beta2-nicotinic acetylcholine receptors heterologously expressed in human SH-EP1 cells. J Biol Chem 2004; 279: 37842-51.
157. Lamb PW, Melton MA, Yakel JL. Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by -amyloid1-42 peptide. J Mol Neurosci 2005; 27: 13-21.
158. Liu Q, Huang Y, Shen J, Steffensen S, Wu J. Functional 72 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid peptides. BMC Neurosci 2012; 13: 155-5.
159. Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 2010; 7: 27-39.
160. Kihara T, Shimohama S, Sawada H, et al. alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 2001; 276: 13541-6.
161. Kihara T, Shimohama S, Sawada H, et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Annl Neurol 1997; 42: 159-63.
162. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 2006; 51: 474-86.
163. Lilja AM, Porras O, Storelli E, Nordberg A, Marutle A. Functional interactions of fibrillar and oligomeric amyloid-with alpha7 nicotinic receptors in Alzheimer's disease. J Alzheimer's Dis JAD 2011; 23: 335-47.
164. Ni R, Marutle A, Nordberg A. Modulation of 7 nicotinic acetylcholine receptor and fibrillar amyloid-interactions in Alzheimer's disease brain. J Alzheimer's Dis 2013; 33: 841-51.
165. Wang H-Y, Bakshi K, Shen C, Frankfurt M, Trocmé-Thibierge C, Morain P. S 24795 limits beta-amyloid-alpha7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies. Biol Psychiatry 2010; 67: 522-30.
166. Nagele RG, D’Andrea MR, Anderson WJ, Wang HY. Intracellular accumulation of -amyloid1–42 in neurons is facilitated by the 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 2002; 110: 199-211.
167. Wang H-Y, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 2009; 29: 10961-73.
168. Klyubin I, Ondrejcak T, Hayes J, et al. Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Ain vivo. Philos Trans R Soc Lond Ser B Biol Sci 2014; 369: 20130147.
169. Chen G, Chen P, Tan H, Ma D, Dou F, Feng J, Yan Z. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease. Neurobiol Aging 2008; 29: 1795-804.
170. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a realworld setting. Curr Med Res Opin 2004; 20: 1747-52.
171. Ritchie CW, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-69.
172. Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J Clin Pharmacol 2006; 46: 8S-16S.
173. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97.
174. Kellar KJ, Martino AM, Hall DP, Jr., Schwartz RD, Taylor RL. High-affinity binding of [3H] acetylcholine to muscarinic cholinergic receptors. J Neurosci 1985; 5: 1577-82.
175. Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007; 11: 491-507.
176. Schrattenholz A, Pereira EF, Roth U, Weber KH, Albuquerque EX, Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996; 49: 1-6.
177. Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003; 305: 1024-36.
178. Brioni JD, Kim DJ, O'Neill AB. Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 1996; 301: 1-5.
179. Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M. Selective alpha7 nicotinic acetylcholine recep tor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain Res 2009; 1265: 65-74.
180. Ren K, King MA, Liu J, et al. The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience 2007; 148: 230-7.
181. Medeiros R, Castello NA, Cheng D, et al. 7 nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles. Am J Pathol 2014; 184: 520-9.
182. Oddo S, Caccamo A, Shepherd JD. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aand synaptic dysfunction. Neuron 2003; 39(3): 409-21.
183. Deardorff WJ, Shobassy A, Grossberg GT. Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication. Exp Rev Neurotherapeutics 2015; 15: 7-17.
184. FORUM Pharmaceuticals Inc. Updates encenicline phase 3 clinical trial programs in Alzheimer’s disease and cognitive impairment in schizophrenia. http://www.businesswire.com/news/home/20150914005855/en/FORU M-Pharmaceuticals-Updates-Encenicline-Phase-3-Clinical.
185. Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012; 62: 1099-110.
186. Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003; 28: 542-51.
187. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8.
188. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7.
189. Gault LM, Ritchie CW, Robieson WZ, Pritchett Y, Othman AA, Lenz RA. A phase 2 randomized, controlled trial of the 7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's Dement Trans Res Clin Intervent 2015; 1: 81-90.
190. Gault LM, Meier A, Florian H, et al. A phase 2 trial of the efficacy and safety of the alpha7 agonist ABT-126 as an add-on treatment in mild-to-moderate alzheimer’s dementia. Alzheimer’s Dement 2014; 10: 917-8.
191. Othman A, Meier A, Ritchie CW, Florian H, Gault LM, Tang Q. Efficacy and safety of the alpha7 agonist abt-126 as a monotherapy treatment in mild-to-moderate alzheimer's dementia: Results of a phase 2B trial. Alzheimer's Dement J Alzheimer's Assoc 2014; 10: 137.
192. Pharmaceuticals M. Press release: Memory pharmaceuticals announces positive Phase 2a results for MEM 3454 in Alzheimer’s Disease. Drugs.com: http: //www.drugs.com/clinical_trials/memory-pharmaceuticalsannounces-positive-phase-2a-results-mem-3454-alzheimer-s-2538.html.
193. Alzforum. Alzforum. http: //www.alzforum.org/therapeutics/rg3487.
194. Vallés AS, Borroni MV, Barrantes FJ. Targeting Brain 7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Rationale and Current Status. CNS drugs 2014; 28: 975-87.
195. Bushell-Embling D. Bionomics licenses BNC375 for up to $558m. LifeScientist: http: //www.lifescientist.com.au/content/biotechnology/article/bionomic s-licenses-bnc375-for-up-to-558m-1114035451.
196. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006; 184: 523-39.
197. Nie H, Wang Z, Zhao W, et al. New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer's disease. Neurosci Lett 2013; 537: 29-34.
198. Dunbar GC, Kuchibhatla RV, Lee G. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol 2011; 25: 1020-9.
199. Frolich L, Ashwood T, Nilsson J, Eckerwall G, Sirocco I. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J Alzheimers Dis 2011; 24: 363-74.
200. Rueter LE, Anderson DJ, Briggs CA, et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev 2004; 10: 167-82.
201. Bain EE, Apostol G, Sangal RB, et al. A randomized pilot study of the efficacy and safety of ABT-089, a novel alpha4beta2 neuronal nicotinic receptor agonist, in adults with attentiondeficit/ hyperactivity disorder. J Clin Psychiatry 2012; 73: 783-9.
202. Apostol G, Abi-Saab W, Kratochvil CJ, et al. Efficacy and safety of the novel alpha(4)beta(2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology (Berl) 2012; 219: 715-25.
203. Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate. Alzheimer Dis 2015; 00: 1-8.
204. Mazurov AA, Kombo DC, Hauser TA, et al. Discovery of (2S, 3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2] oct-3-yl] benzo[b] furan-2-car boxamide (TC-5619), a selective alpha7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. J Med Chem 2012; 55(22): 9793-809.
205. Jucaite A, Ohd J, Potter AS, et al. A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 2014; 231: 1251-65.
206. Kim SY, Choi SH, Rollema H, et al. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2014; 37: 232-45.
207. Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010; 210: 453-69.
208. Ernst M, Heishman SJ, Spurgeon L, London ED. Smoking history and nicotine effects on cognitive performance. Neuropsychopharmacology 2001; 25: 313-9.
209. van Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. BMJ 1991; 302: 1491-4.
210. Ott A, Slooter AJ, Hofman A, et al. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998; 351: 1840-3.
211. Durazzo TC, Mattsson N, Weiner MW, Alzheimer's Disease Neuroimaging I. Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement 2014; 10: S122-45.
212. Tyas SL, White LR, Petrovitch H, et al. Mid-life smoking and latelife dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 2003; 24: 589-96.
213. Perry E, Martin-Ruiz C, Lee M, et al. Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. Eur J Pharmacol 2000; 393: 215-22.
214. Sabbagh MN, Tyas SL, Emery SC, et al. Smoking affects the phenotype of Alzheimer disease. Neurology 2005; 64: 1301-3.
215. Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 1997; 94: 450-4.
216. Nordberg A, Hellstrom-Lindahl E, Lee M, et al. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem 2002; 81: 655-8.
217. Oddo S, Caccamo A, Green KN, et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci USA 2005; 102: 3046-51.
218. Lester HA, Xiao C, Srinivasan R, et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J 2009; 11: 167-77.
219. Echeverria V, Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci Therapeut 2012; 18: 517-23.
220. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45: 1041-51.
221. Chan DK, Woo J, Ho SC, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry 1998; 65: 781-4.
222. Miwa JM, Lester HA, Walz A. Optimizing cholinergic tone through lynx modulators of nicotinic receptors: Implications for plasticity and nicotine addiction. Physiology 2012; 27: 187-99.
223. Bamezai A. Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp 2004; 52: 255-66.
224. Dessaud E, Salaün D, Gayet O, Chabbert M, DeLapeyrière O. Identification of lynx2, a novel member of the ly-6/neurotoxin superfamily, expressed in neuronal subpopulations during mouse development. Mol Cell Neurosci 2006; 31: 232-42.
225. Darvas M, Morsch M, Racz I, Ahmadi S, Swandulla D, Zimmer A. Modulation of the Ca2+ conductance of nicotinic acetylcholine receptors by Lypd6. Eur Neuropsychopharmacol 2009; 19: 670-81.
226. Jensen MM, Arvaniti M, Mikkelsen JD, et al. Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer’s disease. Neurobiol Aging 2015; 36: 1629-38.
227. Miwa JM, Ibanez-Tallon I, Crabtree GW, et al. lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 1999; 23: 105-14.
228. Chimienti F, Hogg RC, Plantard L, et al. Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. Human Mol Genet 2003; 12: 3017-24.
229. Davies A, Simmons DL, Hale G, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 1989; 170: 637-54.
230. Galat A. The three-fingered protein domain of the human genome. Cell Mol Life Sci 2008; 65: 3481-93.
231. Tsetlin VI. Three-finger snake neurotoxins and Ly6 proteins targeting nicotinic acetylcholine receptors: pharmacological tools and endogenous modulators. Trends Pharmacol Sci 2015; 36: 109-123.
232. Ibañez-Tallon I, Miwa JM, Wang HL, et al. Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. Neuron 2002; 33: 893-903.
233. Thomsen MS, Arvaniti M, Jensen MM, et al. Lynx1 interacts with multiple nicotinic acetylcholine receptor subtypes in the human brain: Relation to Alzheimer’s disease-like pathology. Society for Neuroscience Conference Abstract 2014.
234. Miwa JM, Stevens TR, King SL, et al. The prototoxin lynx1 acts on nicotinic acetylcholine receptors to balance neuronal activity and survival in vivo. Neuron 2006; 51: 587-600.
235. Miwa JM, Walz A. Enhancement in Motor Learning through Genetic Manipulation of the Lynx1 Gene. PloS One 2012; 7: e43302-e43302.
236. Lyukmanova EN, Shenkarev ZO, Shulepko MA, et al. NMR structure and action on nicotinic acetylcholine receptors of watersoluble domain of human LYNX1. J Biol Chem 2011; 286: 10618-27.
237. Morishita H, Miwa JM, Heintz N, Hensch TK. Lynx1, a cholinergic brake, limits plasticity in adult visual cortex. Science (New York, N.Y.) 2010; 330: 1238-40.
238. Nichols WA, Henderson BJ, Yu C, et al. Lynx1 Shifts 42 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum. J Biol Chem 2014; 289: 31423-32.
239. Tekinay AB, Nong Y, Miwa JM, et al. A role for LYNX2 in anxiety-related behavior. Proc Natl Acad Sci USA 2009; 106: 4477-82.
240. Puddifoot CA, Wu M, Sung RJ, Joiner WJ. Ly6h regulates trafficking of alpha7 nicotinic acetylcholine receptors and nicotineinduced potentiation of glutamatergic signaling. J Neurosci 2015; 35: 3420-30.
241. Thomsen MS, Jensen MM, Cinar B, et al. Perinatal nicotine administration increases hippocampal Lypd6 levels in adulthood. Society for Neuroscience abstract 2013.
242. Reiter RE, Gu Z, Watabe T, Thomas G, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95: 1735-40.
243. Hruska M, Keefe J, Wert D, et al. Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci 2009; 29: 14847-54.
244. Adams JP, Sweatt JD. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annl Rev Pharmacol Toxicol 2002; 42: 135-63.
245. Lyukmanova EN, Shulepko MA, Buldakova SL, et al. Watersoluble LYNX1 residues important for interaction with muscletype and/or neuronal nicotinic receptors. J Biol Chem 2013; 288: 15888-99.
246. Wang H-YY, Bakshi K, Shen C, Frankfurt M, Trocmé-Thibierge C, Morain P. S 24795 Limits -Amyloid-7 nicotinic receptor interaction and reduces Alzheimer's disease-like pathologies. Biol Psychiatry 2010; 67: 522-30.
247. Kobayashi A, Parker RL, Wright AP, et al. Lynx1 supports neuronal health in the mouse dorsal striatum during aging: an ultrastructural investigation. J Mol Neurosci 2014; 53: 525-36.
248. Yang LB, Li R, Meri S, Rogers J, Shen Y. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci 2000; 20: 7505-9.
249. Tirosh Y, Ofer D, Eliyahu T, Linial M. Short toxin-like proteins attack the defense line of innate immunity. Toxins (Basel) 2013; 5: 1314-31.
250. Demars MP, Morishita H. Cortical parvalbumin and somatostatin GABA neurons express distinct endogenous modulators of nicotinic acetylcholine receptors. Mol Brain 2014; 7: 75.
251. Petersen CP, Reddien PW. Wnt Signaling and the Polarity of the Primary Body Axis. Cell 2009; 139: 1056-68.
252. Nusse R, Brown A, Papkoff J, et al. A new nomenclature for int-1 and related genes: The Wnt gene family. Cell 1991; 64: 231.
253. Clevers H, Nusse R. Wnt/-Catenin signaling and disease. Cell 2012; 149: 1192-205.
254. Inestrosa NC, Varela-Nallar L. Wnt signalling in neuronal differentiation and development. Cell Tissue Res 2014; 359: 215-23.
255. Logan CY, Nusse R. The wnt signaling pathway in development and disease. Ann Rev Cell Develop Biol 2004; 20: 781-810.
256. Purro SA, Ciani L, Hoyos-Flight M, Stamatakou E, Siomou E, Salinas PC. Wnt regulates axon behavior through changes in microtubule growth directionality: a new role for Adenomatous Polyposis Coli. J Neurosci 2008; 28: 8644-54.
257. Lucas FR, Salinas PC. WNT-7a induces axonal remodeling and increases synapsin I Levels in cerebellar neurons. Develop Biol 1997; 192: 31-44.
258. Ciani L, Boyle KA, Dickins E, et al. Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca2+/Calmodulin-dependent protein kinase II. Proc Natl Acad Sci 2011; 108: 10732-7.
259. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol 2012; 7: 788-807.
260. Zhang Z, Hartmann H, Do VM, et al. Destabilization of betacatenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 1998; 395: 698-702.
261. Caricasole A, Copani A, Caraci F, et al. Induction of Dickkopf-1, a negative modulator of the wnt pathway, is associated with neuronal degeneration in Alzheimer's Brain. J Neurosci 2004; 24: 6021-7.
262. Rosi MC, Luccarini I, Grossi C, et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem 2010; 112: 1539-51.
263. Caruso A, Motolese M, Iacovelli L, et al. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J Neurochem 2006; 98: 364-71.
264. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 2010; 11: 77-86.
265. De Ferrari GV, Papassotiropoulos A, Biechele T, et al. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci USA 2007; 104: 9434-9.
266. Liu CC, Tsai CW, Deak F, et al. Deficiency in LRP6-Mediated wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer’s Disease. Neuron 2014; 84: 63-77.
267. Takashima A, Noguchi K, Michel G, et al. Exposure of rat hippocampal neurons to amyloid peptide (25–35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3. Neurosci Lett 1996; 203: 33-6.
268. Takashima A, Honda T, Yasutake K, et al. Activation of tau protein kinase I/glycogen synthase kinase-3 by amyloid peptide (25–35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 1998; 31: 317-23.
269. Purro SA, Dickins EM, Salinas PC. The secreted wnt antagonist Dickkopf-1 Is required for amyloid -Mediated synaptic loss. J Neurosci 2012; 32: 3492-8.
270. Magdesian MH, Carvalho MMVF, Mendes FA, et al. Amyloid-binds to the extracellular cysteine-rich domain of frizzled and inhibits Wnt/-catenin signaling. J Biol Chem 2008; 283: 9359-68.
271. Li B, Zhong L, Yang X, Andersson T, Huang M, Tang S-J. WNT5A signaling contributes to A-induced neuroinflammation and neurotoxicity. PloS One 2011; 6: e22920-e22920.
272. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp cell Res 2004; 297: 186-96.
273. Quintanilla RA, Muñoz FJ, Metcalfe MJ, et al. Trolox and 17-Estradiol protect against amyloid -Peptide neurotoxicity by a mechanism that involves modulation of the wnt signaling pathway. J Biol Chem 2005; 280: 11615-25.
274. Chacón MA, Varela-Nallar L, Inestrosa NC. Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Aoligomers. J Cell Physiol 2008; 217: 215-27.
275. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1[Delta] E9 mouse model of Alzheimer's disease. Mol Psychiatry 2009; 15: 272-85.
276. Godoy JA, Arrazola MS, Ordenes D, Silva-Alvarez C, Braidy N, Inestrosa NC. Wnt-5a ligand modulates mitochondrial fissionfusion in rat hippocampal neurons. J Biol Chem 2014; 289: 36179-93.
277. Silva-Alvarez C, Arrázola MS, Godoy JA, Ordenes D, Inestrosa NC. Canonical Wnt signaling protects hippocampal neurons from Aoligomers: role of non-canonical Wnt-5a/Ca(2+) in mitochondrial dynamics. Front Cell Neurosci 2013; 7: 97-97.
278. Ríos JA, Cisternas P, Arrese M, Barja S, Inestrosa NC. Is Alzheimer's disease related to metabolic syndrome? A Wnt Signaling Conundrum. Prog Neurobiol 2014; 121: 125-46.
279. Sakurai R, Cerny LM, Torday JS, Rehan VK. Mechanism for nicotine-induced up-regulation of Wnt signaling in human alveolar interstitial fibroblasts. Exp Lung Res 2011; 37: 144-54.
280. Zou W, Zou Y, Zhao Z, Li B, Ran P. Nicotine-induced epithelialmesenchymal transition via Wnt/beta-catenin signaling in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2013; 304: L199-209.
281. Inestrosa NC, Godoy JA, Vargas JY, et al. Nicotine prevents synaptic impairment induced by amyloid-oligomers through 7-nicotinic acetylcholine receptor activation. Neuromol Med 2013; 15: 549-69.
282. Farías GG, Vallés AS, Colombres M, et al. Wnt-7a induces presynaptic colocalization of alpha 7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. J Neurosci 2007; 27: 5313-25.
283. Jensen M, Hoerndli FJ, Brockie PJ, et al. Wnt signaling regulates acetylcholine receptor translocation and synaptic plasticity in the adult nervous system. Cell 2012; 149: 173-87.
284. Özhan G, Sezgin E, Wehner D, et al. Lypd6 enhances wnt/-catenin signaling by promoting lrp6 phosphorylation in raft plasma Membrane Domains. Develop Cell 2013; 26: 331-45.
285. Liu C, Wang Y, Smallwood PM, Nathans J. An essential role for Frizzled5 in neuronal survival in the parafascicular nucleus of the thalamus. J Neurosci 2008; 28: 5641-53.
286. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-36.
287. Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1 NMDA receptor–dependent synaptic plasticity in spatial memory. Cell 1996; 87: 1327-38.
288. McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science 1995; 269: 1692-6.
289. Yamazaki Y, Jia Y, Niu R, Sumikawa K. Nicotine exposure in vivo induces long-lasting enhancement of NMDA receptor-mediated currents in the hippocampus. Eur J Neurosci 2006; 23: 1819-28.
290. Aramakis VB, Metherate R. Nicotine selectively enhances NMDA receptor-mediated synaptic transmission during postnatal development in sensory neocortex. J Neurosci 1998; 18: 8485-95.
291. Lin H, Vicini S, Hsu FC, et al. Axonal 7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons. Proc Natl Acad Sci USA 2010; 107: 16661-6.
292. Wang F, Chen H, Steketee JD, Sharp BM. Upregulation of ionotropic glutamate receptor subunits within specific mesocorticolimbic regions during chronic nicotine self-administration. Neuropsychopharmacology 2007; 32: 103-9.
293. Delibas N, Doguc DK, Sutcu R, Eroglu E, Gökalp O. EFFECT of nicotine on hippocampal nicotinic acetylcholine alpha7 receptor and NMDA receptor subunits 2A and 2B expression in young and old rats. Int J Neurosci 2005; 115: 1151-63.
294. Lin H, Hsu F-CC, Baumann BH, Coulter DA, Lynch DR. Cortical synaptic NMDA receptor deficits in 7 nicotinic acetylcholine receptor gene deletion models: Implications for neuropsychiatric diseases. Neurobiol Dis 2014; 63: 129-40.
295. Salamone A, Zappettini S, Grilli M, et al. Prolonged nicotine exposure down-regulates presynaptic NMDA receptors in dopaminergic terminals of the rat nucleus accumbens. Neuropharmacology 2014; 79: 488-97.
296. Liu D, Gu X, Zhu J, et al. Medial prefrontal activity during delay period contributes to learning of a working memory task. Science 2014; 346: 458-63.
297. Wang Y, Wang Z, Wang J, et al. The modulation of nicotinic acetylcholine receptors on the neuronal network oscillations in rat hippocampal CA3 area. Scientific Rep 2015; 5: 9493-3.
298. Zappettini S, Grilli M, Olivero G, et al. Nicotinic 7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens. Front Cell Neurosci 2014; 8: 332-2.
299. Oda A, Yamagata K, Nakagomi S, et al. Nicotine induces dendritic spine remodeling in cultured hippocampal neurons. J Neurochem 2014; 128: 246-55.
300. Ishibashi M, Yamazaki Y, Miledi R, Sumikawa K. Nicotinic and muscarinic agonists and acetylcholinesterase inhibitors stimulate a common pathway to enhance GluN2B-NMDAR responses. Proc Natl Acad Sci USA 2014; 111: 12538-43.
301. Li S, Li ZZX, Pei L, Le ADADD, Liu F. The 7nACh-NMDA receptor complex is involved in cue-induced reinstatement of nicotine seeking. J Exp 2012; 209: 2141-7.
302. Li S, Nai Q, Lipina TV, Roder JC, Liu F. 7nAchR/NMDAR coupling affects NMDAR function and object recognition. Mol Brain 2013; 6: 58.
303. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
304. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005; 8: 1051-8.
305. Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S. The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function. Neuropharmacology 2015: 1-15.
306. Hilt D, Gawryl M, Koenig G. Evp-6124: Safety, Tolerability and cognitive effects of a novel A7 nicotinic receptor agonist in Alzheimer'S disease patients on stable donepezil or rivastigmine therapy. Alzheimer's Dement J Alzheimer's Assoc 2009; 5: e32.
307. Hilt D, Gawryl M, Koenig G, Dgetluck N, Moebius H. EVP-6124, a selective alpha-7 partial agonist, has positive effects on cognition and clinical function in mild-to-moderate Alzheimer’s disease patients: results of a six-month, double-blind, placebo controlled, dose ranging study. Alzheimer’s Dement 2012; 8: S746.
308. Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, Dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate alzheimer disease. Alzheimer Dis Assoc Disord 2015; 29(3): 192-9.